SUPPLEMENTAL MATERIAL 1.
Subgroup Analysis of Overall Survival
A stratified analysis was performed of variables identified by the Multivariate
Cox regression analysis as independent predictors of overall survival. Patients with
TNM stage I were evaluated. Patients in the Sorafenib-RFA group (n=41) had a
median survival of 189.6 weeks (95% CI: 162.7 to 216.5 weeks) while patients in the
RFA group (n=42) had a median survival of 133.7 weeks (95% CI: 107.7 to 159.7
weeks, Fig 1B). Patients with TNM stage Ⅱ or Ⅲa were evaluated. Patients in the
Sorafenib-RFA group (n=23) had a median survival of 97.9 weeks (95% CI: 60.8 to
135.0 weeks) while patients in the RFA group (n=22) had a median survival of 70.7
weeks (95% CI: 39.2 to 102.2 weeks, Fig 1C).
Patients with solitary hepatic tumors were evaluated. The median survival of the
Sorafenib-RFA group (n=38) was 187.1 weeks (95% CI: 162.4 to 211.9 weeks). The
median survival of the RFA group (n=47) was 144.0 weeks (95% CI: 117.2 to 170.7
weeks, Fig 1 D). Patients with multiple hepatic tumors were evaluated. The median
survival of the Sorafenib-RFA group (n=26) was 57.1 weeks (95% CI: 2.50 to 111.7
weeks). The median survival of the RFA group (n=17) was 92.3 weeks (95% CI: 83.3
to 101.3 weeks, Fig 2 A).
A preliminary analysis indicated an optimal cut-off value for tumor diameter was 3.65
cm. Patients with tumor size less than 3.65 cm were evaluated. The median survival
of the Sorafenib-RFA group (n=47) was 189.9 weeks (95% CI: 161.0 to 218.9 weeks).
The median survival of the RFA group (n=50) was 134.3 weeks (95% CI: 107.0 to
1
161.7 weeks, Fig 2 B). Tumors equal to or larger than 3.65cm were evaluated. The
median survival of the Sorafenib-RFA group (n=17) was 135.0 weeks (95% CI: 78.0
to 191.9 weeks). The median survival of the RFA group (n=14) was 93.1 weeks (95%
CI: 83.7 to 102.5 weeks, Fig 2 C).
2
SUPPLEMENTAL MATERIAL 2.
Supplement TABLE 1. RFA equipment list.
Serial
system
1
RITA 1500/1500 X
Country
U.S.A
2
U.S.A
3
4
5
Manufacturer
RITA Medical
Systems, Inc.
RF-2000
Radiotherapeuti
c.inc
RFA-1315 Multi pole RF ablation Beijing bright
instrument
Optoelectronic
Technology
Development
Co., Ltd.
LDRF—120S Multi pole RF ablation Mianyang Lead
instrument
Technology
company
HGCF-3000 cold pole RF ablation Zhuhai
Hokai
instrument
Medical
Instruments Co.,
Ltd
3
China
China
China
Supplement TABLE 2. Univariate COX regression analysis of overall survival.
B
SE
χ2
P
HR
95% CI for
HR
-0.704
0.347
4.106
0.043*
0.495
0.250~0.977
0.001
0.313
0.859
-0.695
0.727
0.017
0.603
0.361
0.393
0.369
0.003
0.270
5.659
3.126
3.884
0.959
0.604
0.017*
0.077
0.049*
1.001
1.368
2.361
0.499
2.068
0.969~1.034
0.419~4.463
1.163~4.792
0.231~1.078
1.004~4.262
Tumor size
0.171
0.053
10.513
1.187
1.070~1.317
HBV
Antivirus
therapy
liver cirrhosis
Previous
resection
Previous RFA
Previous TACE
-0.671
0.847
0.629
0.001**
0.428
0.511
0.097~2.686
-0.250
0.391
0.410
0.522
0.779
0.362~1.675
0.118
0.191
0.380
0.538
1.125
0.774~1.636
-0.058
0.360
0.026
0.873
0.944
0.466~1.913
-0.273
-0.046
0.415
0.363
0.430
0.016
0.512
0.899
0.761
0.955
0.337~1.719
0.469~1.945
Variables
Sorafenib
administration
Age
Gender
TNM stage
BCLC stage
Tumor number
*P<0.05；**P<0.01.
4
Supplement TABLE 3. Multivariate Cox regression analysis of tumor
recurrence.
Variables
Sorafenib
administration
TNM stage
Tumor number
Antivirus
therapy
Previous TACE
B
SE
χ2
1.009
0.339
8.866
-0.876
0.884
0.540
0.406
0.406
0.272
-0.782
0.395
HR
95% CI for HR
0.003**
2.744
1.412~5.332
4.659
4.738
3.937
0.031*
0.029*
0.047*
0.416
2.420
1.715
0.188~0.923
1.092~5.363
1.007~2.923
3.926
0.048*
0.458
0.211~0.992
*P<0.05；**P<0.01.
5
P